Redmile Group LLC purchased a new stake in Juno Therapeutics, Inc. (NASDAQ:JUNO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 2,219,616 shares of the biopharmaceutical company’s stock, valued at approximately $66,344,000. Juno Therapeutics makes up 4.0% of Redmile Group LLC’s investment portfolio, making the stock its 6th largest holding. Redmile Group LLC owned 2.09% of Juno Therapeutics at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of JUNO. Vanguard Group Inc. boosted its stake in Juno Therapeutics by 2.1% in the second quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock valued at $187,879,000 after acquiring an additional 131,864 shares during the last quarter. BlackRock Inc. boosted its stake in Juno Therapeutics by 2.6% in the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock valued at $128,357,000 after acquiring an additional 110,503 shares during the last quarter. State Street Corp boosted its stake in Juno Therapeutics by 7.4% in the second quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock valued at $96,742,000 after acquiring an additional 222,754 shares during the last quarter. Capital World Investors boosted its stake in Juno Therapeutics by 13.8% in the second quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company’s stock valued at $72,483,000 after acquiring an additional 295,000 shares during the last quarter. Finally, Jennison Associates LLC bought a new position in Juno Therapeutics in the second quarter valued at approximately $22,689,000. 67.38% of the stock is owned by institutional investors and hedge funds.
In related news, insider Sunil Agarwal sold 7,285 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total value of $326,076.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Robert Azelby sold 12,850 shares of the firm’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $44.95, for a total value of $577,607.50. Following the completion of the sale, the executive vice president now owns 37,439 shares of the company’s stock, valued at $1,682,883.05. The disclosure for this sale can be found here. Insiders have sold a total of 85,004 shares of company stock valued at $3,551,561 over the last quarter. Corporate insiders own 15.26% of the company’s stock.
Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) traded up 3.10% during midday trading on Tuesday, reaching $44.21. 1,515,439 shares of the company’s stock traded hands. The company has a 50 day moving average of $43.16 and a 200 day moving average of $30.34. Juno Therapeutics, Inc. has a 52-week low of $17.52 and a 52-week high of $47.03. The firm’s market cap is $4.64 billion.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). The business had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The company’s revenue for the quarter was down 22.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.64) earnings per share. On average, equities analysts predict that Juno Therapeutics, Inc. will post ($3.08) EPS for the current fiscal year.
A number of equities analysts have issued reports on the stock. Vetr cut shares of Juno Therapeutics from a “hold” rating to a “sell” rating and set a $28.47 price objective on the stock. in a research note on Monday, August 7th. Wells Fargo & Company reissued an “outperform” rating and set a $54.00 price target (up from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th. BidaskClub raised shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 20th. Zacks Investment Research raised shares of Juno Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $44.00 price target on shares of Juno Therapeutics in a research report on Friday, October 6th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $37.83.
ILLEGAL ACTIVITY WARNING: This piece was reported by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/redmile-group-llc-invests-66-34-million-in-juno-therapeutics-inc-juno/1699402.html.
Juno Therapeutics Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with our FREE daily email newsletter.